Table 2.

Summary of phenotypes in whole-lung cells of bleomycin (BLM)- or BLM + pirfenidone-treated mice determined through fluorescence-activated cell sorter analysis in a therapeutic setting ^*

	Percentage of cells
Treatment	CD45-/Col-I-	CD45+/Col-I-	CD45-/Col-I+	CD45+/Col-I + (Fibrocyte)
Saline	64.8 ± 9.5	9.76 ± 13.6	15.3 ± 21.4	10.1 ± 1.7
BLM	25.1 ± 3.0	16.1 ± 22.0	33.1 ± 25.0	25.6 ± 5.9
BLM + pirfenidone	47.8 ± 7.2	6.8 ± 8.7	27.8 ± 7.8	17.6 ± 6.4

^*Data are shown as the percentage of cells that are positive (+) or negative (−) for CD45 or collagen I (Col-I) in whole-lung cells. Data shown represent the means ± standard error from 6 saline-, BLM- or BLM + pirfenidone-treated mice, respectively, and are representative of 2 independent experiments.